Pozen looking to US submission in 2H 2012 for secondary CV prevention drug
This article was originally published in Scrip
Executive Summary
US company Pozen said it is working towards a US submission for its investigational oral product, PA32540, for the secondary prevention of cardiovascular disease, in the second half of next year, and will seek one or more strategic partners to "maximise the sales potential of PA32540 both in the US and globally".